DeepMed Research

IPSEN, OOO

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1929-01-01

Employees: 5.7K

Market Cap: $9.8B

Website: https://www.ipsen.com/

Clinical Trials

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines

Phase 1

Recruiting

Conditions: Moderate to Severe Upper Facial Lines

Interventions: Biological: IPN10200 Placebo
Biological: IPN10200
Biological: Dysport

First Posted Date: 2021-03-29

Last Posted Date: 2025-04-30

Lead Sponsor: Ipsen

Target Recruit Count: 727

Registration Number: NCT04821089

Locations: 🇫🇷
Palais de Flore, Lyon, France
🇫🇷
MEDITI - Clinique Del Mar, Antibes, France
🇫🇷
Clinique de Chirurgie Esthétique Iéna, Paris, France

and more 6 locations

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

Phase 1

Active, not recruiting

Conditions: Spasticity

Interventions: Biological: IPN10200
Drug: Placebo
Biological: Dysport

First Posted Date: 2021-02-12

Last Posted Date: 2025-05-01

Lead Sponsor: Ipsen

Target Recruit Count: 240

Registration Number: NCT04752774

Locations: 🇺🇸
Rancho Los Amigos National Rehab, Downey, California, United States
🇺🇸
Kansas Institute of Research, Overland Park, Kansas, United States
🇺🇸
Quest Research Institute, Farmington Hills, Michigan, United States

and more 36 locations

Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.

Phase 3

Completed

Conditions: Central Precocious Puberty

Interventions: Drug: Triptorelin pamoate 15mg

First Posted Date: 2021-02-03

Last Posted Date: 2024-08-01

Lead Sponsor: Ipsen

Target Recruit Count: 32

Registration Number: NCT04736602

Locations: 🇨🇳
Tangshan Maternal & Child Health Hospital, Tangshan, China
🇨🇳
Chengdu Women's and Children's Central Hospital, Chengdu, China
🇨🇳
Jiangxi Provincial Children's Hospital, Nanchang, China

and more 4 locations

Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines.

Phase 1

Terminated

Conditions: Moderate Upper Facial Lines
Severe Upper Facial Lines

Interventions: Biological: IPN59011
Drug: Placebo
Biological: Azzalure

First Posted Date: 2021-02-03

Last Posted Date: 2023-07-14

Lead Sponsor: Ipsen

Target Recruit Count: 56

Registration Number: NCT04736745

Locations: 🇩🇪
Clinical Research Centre (CRS), Berlin, Germany

An International Cross-sectional Survey to Evaluate the Burden of Fibrodysplasia Ossificans Progressiva (FOP) on Patients and Their Families.

Completed

Conditions: Fibrodysplasia Ossificans Progressiva

First Posted Date: 2020-12-11

Last Posted Date: 2021-05-21

Lead Sponsor: Ipsen

Target Recruit Count: 411

Registration Number: NCT04665323

Locations: 🇺🇸
Ipsen Central Contact, Cambridge, Massachusetts, United States

United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting

Completed

Conditions: Neuroendocrine Tumours (NET)

First Posted Date: 2020-12-02

Last Posted Date: 2024-12-17

Lead Sponsor: Ipsen

Target Recruit Count: 80

Registration Number: NCT04649580

Locations: 🇬🇧
University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
🇬🇧
Cardiff and Vale University LHB, Cardiff, United Kingdom
🇬🇧
Royal Free London NHS Foundation Trust, London, United Kingdom

and more 2 locations

Relation Between Dose and Time to Reinjection of Botulinum Toxin-A in Patient With Poststroke Spasticity From a Real-world Healthcare Insurance Database.

Completed

Conditions: Post Stroke Spasticity

First Posted Date: 2020-12-02

Last Posted Date: 2020-12-02

Lead Sponsor: Ipsen

Target Recruit Count: 451

Registration Number: NCT04649632

Locations: 🇳🇱
Ipsen Facility, Hoofddorp, Netherlands

Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: Cabozantinib
Drug: Axitinib

First Posted Date: 2020-11-19

Last Posted Date: 2021-02-01

Lead Sponsor: Ipsen

Target Recruit Count: 1540

Registration Number: NCT04637204

Locations: 🇬🇧
Ipsen Facility, Slough, United Kingdom

Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.

Phase 1

Withdrawn

Conditions: Colorectal Cancer
Pancreatic Ductal Adenocarcinoma

Interventions: Drug: 111In-IPN01087 High dose
Drug: 111In-IPN01087 Low dose

First Posted Date: 2020-11-17

Last Posted Date: 2022-08-24

Lead Sponsor: Ipsen

Registration Number: NCT04632199

Locations: 🇫🇷
Centre Léon Bérard, Léon, France
🇧🇪
UZ Leuven, Leuven, Belgium
🇫🇷
CHU de Nantes - Hôpital Hôtel Dieu, Nantes, France

and more 2 locations

Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France.

Withdrawn

Conditions: Renal Cell Carcinoma

First Posted Date: 2020-10-30

Last Posted Date: 2020-12-21

Lead Sponsor: Ipsen

Registration Number: NCT04609800

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy